arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

BELITE BIO, INC

BLTE

$168.93 ▼ -6.22 (-3.55%) at close

7 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

BELITE BIO, INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $5.7B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -10.9% ↗

FCF / Share $-1.10 ↘

Trailing P/E —

Price / Book 8.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-77.61M

↓ -114.7% —

FCF / Share Free cash flow per share

$-1.10

↓ -15.0% —

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
EPS Growth YoY (%)	-95.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.8% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-88.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	37.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-55.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-114.7% Weak ↓ Weak Declining Year-over-year change in net income	-14.3% Weak ↑ Weak Improving Year-over-year change in net income	-150.1% Weak ↓ Weak Declining Year-over-year change in net income	-30.9% Weak Weak Year-over-year change in net income	-68.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-15.0% Weak ↑ Weak Improving Year-over-year change in free cash flow	14.5% Fair ↑ Fair Improving Year-over-year change in free cash flow	-89.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	24.8% Good Good Year-over-year change in free cash flow	-56.1% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Return on Invested Capital (%)	-10.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	51.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	81.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-10.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-53.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-10.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-167%)	-24.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-265%)	-35.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-333%)	-30.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-303%)	64.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+327%)	81.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+445%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Interest Coverage (x)	-84208.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-1266.72x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-801.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-273.48x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-352.93M	$-31.68M	$-88.16M	$-42.09M	$-17.34M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Basic EPS, GAAP (USD)	$-2.31	$-1.18	$-1.19	$-0.63	$-1.01	$-0.65	—
Free Cash Flow per Share (USD)	$-1.10	$-0.96	$-1.12	$-0.59	$-0.79	$-0.51	—
Book Value per Share (USD)	$19.59	$4.58	$3.10	$1.67	$-1.47	$-0.80	—
Tangible Book Value per Share (USD)	$19.58	$4.58	$3.10	$1.67	$-1.47	$-0.80	—
Basic Weighted Avg Shares (shares)	33.54M	30.54M	26.59M	19.98M	9.57M	8.79M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Working Capital (USD)	$484.39M	$141.02M	$86.31M	$40.70M	$15.80M	—	—
Total Equity (USD)	$770.49M	$145.82M	$90.43M	$41.50M	$-15.09M	$-7.04M	$-3.74M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗
Depreciation Expense (USD)	$172.00K	$164.00K	$139.00K	$64.00K	$30.00K	$17.00K	—
Net Income, GAAP (USD)	$-77.61M	$-36.14M	$-31.63M	$-12.65M	$-9.67M	$-5.75M	—
Operating Cash Flow (USD)	$-36.99M	$-29.23M	$-29.84M	$-11.46M	$-7.47M	$-4.44M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 7 quarters

BELITE BIO, INC

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare BLTE with peers